PharmaFoods International Co., Ltd. (TSE: 2929), the Kyoto-based developer of functional ingredients and direct-marketing health products, reported its cumulative third-quarter results for the fiscal year ending July 2026 (the nine months from August 1, 2025 to April 30, 2026) on June 10, 2026. Consolidated revenue rose 3.7% year-on-year to ¥48,555 million, but the operating line swung deeper into the red: the operating loss widened to ¥1,430 million from ¥217 million a year earlier, and the ordinary loss reached ¥1,545 million versus ¥231 million. The net loss, by contrast, narrowed slightly to ¥1,061 million from ¥1,123 million, with a loss per share of −¥36.67 against −¥39.18 in the prior-year period.
Deliberate advertising front-load to cultivate the next revenue pillars
The widened loss is a function of strategy rather than deteriorating demand. PharmaFoods, which develops functional ingredients from its egg-derived research platform and sells consumer health products via mail order and direct marketing, lifted advertising spending 6.2% year-on-year to ¥30,100 million over the nine months, deliberately front-loading promotion behind its newer growth candidates. While the flagship "Newmo" hair-growth series stayed firm, the company pushed products such as its GABA-based "Sleep Lab" functional drinks and the "Newmo D" drink — launched into supermarkets and drugstores — to build the next generation of revenue pillars. The investment is visibly gaining traction: sales of new products grew 46.6% year-on-year in the period.
Equity ratio slips on the seasonal loss; dividend forecast unchanged
Total assets stood at ¥34,856 million at the end of April, with net assets of ¥10,084 million. The equity ratio declined to 28.9% from 35.4% at the previous fiscal year-end, reflecting the cumulative loss and the working-capital swings that accompany the company's advertising-heavy model. The dividend forecast for the year ending July 2026 is unchanged at ¥25.00 per share (¥12.50 interim + ¥12.50 year-end), signalling management's confidence that the full-year plan remains intact despite the nine-month deficit.
Full-year guidance maintained — a strongly profitable fourth quarter implied
PharmaFoods left its full-year guidance untouched: revenue of ¥67,000 million (+2.7%), operating profit of ¥2,000 million (−15.5%), ordinary profit of ¥2,000 million (−21.7%) and net profit of ¥1,500 million (+307.6%), equivalent to EPS of ¥51.65. Against a nine-month operating loss of ¥1.43 billion, the unchanged targets imply a sharply profitable fourth quarter of roughly ¥3.4 billion in operating profit as advertising spending normalizes and the newly cultivated product lines carry a fuller revenue contribution. Whether the May–July quarter delivers that swing will be the key test of the company's front-loaded marketing strategy.
| Metric | 9M FY7/2026 | 9M FY7/2025 | YoY |
|---|---|---|---|
| Revenue (¥ million) | 48,555 | 46,817 | +3.7% |
| Operating profit (loss) (¥ million) | −1,430 | −217 | n.m. |
| Ordinary profit (loss) (¥ million) | −1,545 | −231 | n.m. |
| Net profit (loss) (¥ million) | −1,061 | −1,123 | n.m. |
| EPS (¥) | −36.67 | −39.18 | n.m. |
| Total assets (¥ million) | 34,856 | — | — |
| Net assets (¥ million) | 10,084 | — | — |
| Equity ratio | 28.9% | 35.4% | −6.5pp |
| Annual dividend forecast (¥) | 25.00 | — | — |
| FY guidance — revenue (¥ million) | 67,000 | — | +2.7% |
| FY guidance — operating profit (¥ million) | 2,000 | — | −15.5% |
| FY guidance — net profit (¥ million) | 1,500 | — | +307.6% |
JapanStockPulse provides informational content only and does not constitute investment advice. Figures are taken from the company's published earnings short report and may be subject to subsequent revision.